Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB102 in Non-Segmental Vitiligo
NCT06905873Phase 1Active, not recruiting
- Sponsor
- Forte Biosciences, Inc.
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in Vitiligo comparing FB102 with Placebo (2 arms). Primary endpoints: Number of participants with treatment-emergent adverse events (TEAEs) and Serious Adverse events (SAE) at 16 weeks, Percent change from Baseline in central read facial-vitiligo area scoring index (F-VASI) at 16 weeks and 1 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
FB102
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT06905873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06905873.